The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial.
The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial.